Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic or Locally Unresectable Solid Tumor”

117 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 117 results

Testing effectiveness (Phase 2)Looking for participantsNCT06051695
What this trial is testing

Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNSCLC+17 more
A2 Biotherapeutics Inc. 474
Early research (Phase 1)Study completedNCT03489343
What this trial is testing

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Who this might be right for
Metastatic CancerSolid TumorLymphoma
Symphogen A/S 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05736731
What this trial is testing

Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultSolid TumorPancreatic Cancer+13 more
A2 Biotherapeutics Inc. 160
Early research (Phase 1)Looking for participantsNCT06440005
What this trial is testing

Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Who this might be right for
CancerAdvanced CancerLocally Advanced Carcinoma+8 more
Angiex, Inc. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06974812
What this trial is testing

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd. 250
Early research (Phase 1)Active Not RecruitingNCT05396833
What this trial is testing

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Who this might be right for
Metastatic or Locally Advanced Unresectable Solid Tumors
EMD Serono Research & Development Institute, Inc. 120
Testing effectiveness (Phase 2)Looking for participantsNCT07105215
What this trial is testing

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

Who this might be right for
Solid Tumors
RemeGen Co., Ltd. 312
Testing effectiveness (Phase 2)Looking for participantsNCT06016062
What this trial is testing

RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Who this might be right for
Solid Tumor
RemeGen Co., Ltd. 221
Early research (Phase 1)Study completedNCT03489369
What this trial is testing

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Who this might be right for
Metastatic CancerSolid TumorLymphoma
Symphogen A/S 15
Early research (Phase 1)Study completedNCT03523390
What this trial is testing

Phase I/Ib Multiple Ascending Dose Study in China

Who this might be right for
Metastatic Solid Tumors
Merck KGaA, Darmstadt, Germany 24
Testing effectiveness (Phase 2)Looking for participantsNCT06038396
What this trial is testing

RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumor
RemeGen Co., Ltd. 48
Testing effectiveness (Phase 2)Study completedNCT03543813
What this trial is testing

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Who this might be right for
Solid Tumor, AdultHead and Neck CancerNon Small Cell Lung Cancer+2 more
CytomX Therapeutics 133
Early research (Phase 1)Looking for participantsNCT04762641
What this trial is testing

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumor
ABL Bio, Inc. 100
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Testing effectiveness (Phase 2)Looking for participantsNCT06911333
What this trial is testing

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor, AdultTumor, SolidSolid Tumor+4 more
Avelos Therapeutics Inc. 36
Testing effectiveness (Phase 2)Looking for participantsNCT05205850
What this trial is testing

RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
RemeGen Co., Ltd. 135
Testing effectiveness (Phase 2)Ended earlyNCT04003623
What this trial is testing

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Who this might be right for
Advanced or Metastatic Solid TumorsFGFR MutationsFGFR Translocations
Incyte Corporation 1
Testing effectiveness (Phase 2)Study completedNCT05774873
What this trial is testing

The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.

Who this might be right for
Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd. 28
Early research (Phase 1)WithdrawnNCT06626256
What this trial is testing

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Who this might be right for
Locally Advanced Cervical CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Malignant Solid Neoplasm+24 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT05923008
What this trial is testing

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd. 182
Load More Results